21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

§ 211.101 Charge-in of components

Subpart F - Production and Process Controls Official text on eCFR Amendment history

Written production and control procedures shall include the following, which are designed to assure that the drug products produced have the identity, strength, quality, and purity they purport or are represented to possess:

(a) The batch shall be formulated with the intent to provide not less than 100 percent of the labeled or established amount of active ingredient.

(b) Components for drug product manufacturing shall be weighed, measured, or subdivided as appropriate. If a component is removed from the original container to another, the new container shall be identified with the following information:

(1) Component name or item code;

(2) Receiving or control number;

(3) Weight or measure in new container;

(4) Batch for which component was dispensed, including its product name, strength, and lot number.

(c) Weighing, measuring, or subdividing operations for components shall be adequately supervised. Each container of component dispensed to manufacturing shall be examined by a second person to assure that:

(1) The component was released by the quality control unit;

(2) The weight or measure is correct as stated in the batch production records;

(3) The containers are properly identified. If the weighing, measuring, or subdividing operations are performed by automated equipment under § 211.68 , only one person is needed to assure paragraphs (c)(1) , (c)(2) , and (c)(3) of this section.

(d) Each component shall either be added to the batch by one person and verified by a second person or, if the components are added by automated equipment under § 211.68 , only verified by one person.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 211.101

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Drugs).

  • Component addition checked by 2nd person 53
  • Measured components for manufacturing 23
  • Verification of component addition 22
  • Batches Formulated to less than 100% 17
  • Weighing/measuring/subdividing supervision 15
  • Component release checked by 2nd person 13

Warning letters citing § 211.101

3 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 211.101

Amendment history

Federal Register documents that created or amended this section.